Skip To Main Content
Sally Turner on Muck Rack

Sally Turner

As seen in: MSN, Nature, Yahoo Finance, Veterinary Record, Patient, Sussex Life, Pharmaceutical-Technology.com, Yahoo Finanzas, Medical Device Network, Drug Science and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sally

Contact Sally, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Gender Pay Gap reporting for Irish SMEs

|
By Sally Turner
| ThinkBusiness.ie
Gender Pay Gap reporting is no longer something that can be ignored by Irish SME employers, warns Sally Turner from Xeinadin Ireland. What began in 2022 with large employers of 250 or more staff now extends, from 2025, to organisations with as few as 50 employees. Under the Act, employers are required to publish gender pay differences using a substantial 20 different metrics concerned with average and median rates of pay and bonus payments.
Open in Who Shared Issue with article?

Nitrous-Oxide: What is it good for?

|
By Sally Turner
| Drug Science
Authors Sally Turner Published August 30, 2024 What is nitrous oxide? Discoveredin 1722 by Dr Joseph Priestley, nitrous oxide (N2O) is now an essential medicine and a popular recreational drug. Nitrous oxide is simply structured, with just two nitrogen atomsand one oxygen atom. It is an analgesic, anxiolytic, a sub-anaesthetic, and a recreational substance. It is used in medicine, dentistry, rocket science, motor racing, agriculture, and catering.
Open in Who Shared Issue with article?

Humira: the highs and lows of the world’s best-selling drug

|
By Sally Turner
| Yahoo Finance Verified
Humira: AbbVie's Revolutionary Drug and Its Impact Sales of AbbVie’s blockbuster drug Humira peaked at $18.9bn last year and, according to analysts at Evaluate Pharma, the product is expected to generate $15.2bn through to 2024. These figures are indicative of the drug’s continued dominance in the global marketplace, but Humira’s success story has not been without its challenges. Barbara Gilmore, a senior industry analyst at Frost & Sullivan reflects on its development.
Open in Who Shared View Duplicates (2) Issue with article?
See all 124 licensed articles (125 Total)